Novacyt (ALNOV.PA) Stock Price
Novacyt Price
Over the last 17 years Novacyt grew revenue by 25.5% annually, reaching 20.40 M GBP. For Novacyt, the net margin of -114.2% is down versus -10.5% a few years ago.
Novacyt stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Novacyt business model & stock analysis
Frequently asked questions about Novacyt
Novacyt SA's business model revolves around the development, manufacturing, and distribution of innovative diagnostic solutions. As a global leader in clinical diagnostics, Novacyt focuses on providing fast, accurate, and easy-to-use testing solutions for infectious diseases, primarily respiratory infections. The company's broad range of products includes molecular and protein-based diagnostic tests, which are utilized by healthcare professionals worldwide to identify and monitor various diseases. Novacyt's business model is built on continuous innovation, strategic partnerships, and a commitment to delivering high-quality diagnostic solutions to improve patient outcomes. With its comprehensive portfolio and strong market presence, Novacyt SA is dedicated to advancing the field of diagnostics and meeting the evolving needs of the healthcare industry.
Novacyt SA primarily operates in the healthcare and biotechnology industries.
The main competitors of Novacyt SA in the market include companies such as PerkinElmer, Inc., Quidel Corporation, and Abbott Laboratories.
Novacyt SA is a renowned biotechnology company specializing in clinical diagnostics. Founded in 2006, Novacyt has since emerged as a global leader in the field. With a strong focus on research and development, the company has developed innovative solutions for the rapid detection and diagnosis of infectious diseases and various types of cancer. Novacyt's cutting-edge technology has gained recognition worldwide, enabling accurate and timely results. Through strategic partnerships and collaborations, Novacyt continues to expand its product portfolio and enhance its presence in international markets. With a commitment to improving global healthcare, Novacyt SA remains at the forefront of innovative diagnostics solutions.
Novacyt SA has achieved several significant milestones. Notably, the company developed and launched its NOVAprep® liquid-based cytology system, providing an innovative solution for cervical cancer screening. Furthermore, Novacyt SA successfully acquired Primerdesign Ltd, a molecular diagnostics company specializing in infectious diseases, expanding its product portfolio and market reach. The company also received Emergency Use Authorization from the US FDA for its COVID-19 testing kit, allowing for rapid and accurate diagnosis during the global pandemic. Novacyt SA's continuous commitment to innovation and strategic acquisitions has positioned it as a prominent player in the field of diagnostics and molecular testing.
Novacyt SA is primarily present in various countries and regions worldwide. As a global biotechnology company, Novacyt SA has established its presence in key markets such as Europe, including France, Germany, and the United Kingdom. Additionally, the company has expanded its operations into North America, with a strong focus on the United States. Novacyt SA also maintains a significant presence in other regions, including Asia, Latin America, and the Middle East. With its international reach, Novacyt SA is committed to serving the needs of customers and stakeholders across diverse geographies, contributing to its overall growth and success.
Novacyt SA is a leading international diagnostics company that prides itself on its commitment to high values and corporate philosophy. With a focus on innovation, Novacyt prioritizes providing accurate and reliable diagnostic solutions to improve global healthcare outcomes. The company's core values revolve around quality, integrity, and collaboration. Novacyt SA aims to meet the highest standards in every aspect of its operations, from research and development to manufacturing and customer support. By embracing a customer-centric approach and fostering partnerships, Novacyt SA strives to deliver impactful diagnostic solutions and contribute to the advancement of healthcare worldwide.
7 analysts currently rate the Novacyt stock: 0 recommend buying, 2 holding and 5 selling. For 2026, analysts expect Novacyt to generate revenue of 30.53 M GBP and earnings per share of -0.13 GBP.
Converted at the current exchange rate, the Novacyt share trades at 0.01 EUR (0.00 GBP).
The Novacyt share (ALNOV.PA) is listed on 8 stock exchanges, including: London (NCYT.L), Frankfurt (NYZ.F), München (NYZ.MU), Düsseldorf (NYZ.DU), Paris (ALNOV.PA).
Novacyt SA is a multinational company that offers innovative diagnostic products and services for clinical diagnostics, life science research, and biopharmaceuticals. The company specializes in the development, manufacturing, and marketing of products for the diagnostics of infectious diseases and cancer. The core business of Novacyt SA is the development and marketing of molecular diagnostic tests for a variety of infectious diseases and types of cancer. The tests are specifically used for in vitro diagnostics and are based on polymerase chain reaction (PCR) technology. The tests are designed for rapid and accurate diagnosis of infectious diseases such as Covid-19, influenza, HIV, hepatitis, and tuberculosis, as well as cancer types such as prostate cancer and lung cancer. Novacyt SA operates in two business areas: diagnostics and biopharma. In the diagnostics sector, the company develops and markets molecular diagnostic tests used for the diagnosis of infectious diseases and cancer. The products of the diagnostics business include the NOVAprep cytology supplement and the RUBIDIUM radionuclide. In the biopharma sector, Novacyt SA produces and markets recombinant proteins and antibodies for research and development of innovative therapeutics and vaccines. The products of the biopharma business include purified beta-lactamase, cystatin C, and CD20, essential components for the development of cancer therapeutics and vaccines. Novacyt SA is focused on strengthening its market position in the diagnostics and biopharma sectors through the expansion of its portfolio of diagnostic tests and the development of new products for biopharma research. Additionally, Novacyt SA continuously conducts research and development activities to bring future products for the diagnosis of infectious diseases and types of cancer to the market. Novacyt SA has a strong presence in the global market and operates in over 100 countries worldwide. The company is oriented towards collaborating with partners in Europe, the Middle East, Africa, and Asia to market its products and services in different regions across the world. Overall, Novacyt SA has structured its business model around two pillars: molecular diagnostic tests and biopharma products. The company specializes in the development of products for the diagnostics of infectious diseases and cancer and aims to expand its presence in the global market and broaden its portfolio of diagnostic tests and biopharma products.
The expected revenue of Novacyt is 30.53 M GBP. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Novacyt is -8.86 M GBP. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Novacyt is currently -0.04. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Novacyt stock.
The price-to-sales ratio (P/S) of Novacyt is currently 0.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Novacyt stock.
The Eulerpool Quality Score for Novacyt is 2/10.
The ISIN of Novacyt is FR0010397232. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Novacyt is A12CFH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Novacyt is ALNOV.PA. The ticker symbol is used to trade Novacyt shares on the stock exchange.
Novacyt stock
Novacyt Peer Group
Novacyt Ticker
Novacyt FIGI
All fundamentals and in-depth analysis of Novacyt
Our stock analysis for Novacyt stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novacyt. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.